MDx Firm AdvanDx Pulls in $12M | GenomeWeb

NEW YORK (GenomeWeb News) – AdvanDx, a provider of molecular diagnostics for pathogen identification, said today that it has closed a $12 million Series B-1 financing round.

The financing will go toward expansion of the Woburn, Mass.-based company's product offerings and its sales and marketing operations in the US and abroad, it said.

Merck Global Health Innovation Fund led the round and was joined by existing investors SLS Ventures and LD Pensions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.